JP2007508298A5 - - Google Patents

Download PDF

Info

Publication number
JP2007508298A5
JP2007508298A5 JP2006533831A JP2006533831A JP2007508298A5 JP 2007508298 A5 JP2007508298 A5 JP 2007508298A5 JP 2006533831 A JP2006533831 A JP 2006533831A JP 2006533831 A JP2006533831 A JP 2006533831A JP 2007508298 A5 JP2007508298 A5 JP 2007508298A5
Authority
JP
Japan
Prior art keywords
group
hydroxy
pharmaceutical composition
hydrogen
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2006533831A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007508298A (ja
Filing date
Publication date
Priority claimed from US10/680,881 external-priority patent/US7704980B2/en
Application filed filed Critical
Publication of JP2007508298A publication Critical patent/JP2007508298A/ja
Publication of JP2007508298A5 publication Critical patent/JP2007508298A5/ja
Ceased legal-status Critical Current

Links

JP2006533831A 2003-10-08 2004-07-23 2−メチレン−19−ノル−ビタミンd化合物を用いた炎症性腸疾患の治療 Ceased JP2007508298A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/680,881 US7704980B2 (en) 2003-10-08 2003-10-08 Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin D compounds
PCT/US2004/023586 WO2005039592A1 (en) 2003-10-08 2004-07-23 Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin d compounds

Publications (2)

Publication Number Publication Date
JP2007508298A JP2007508298A (ja) 2007-04-05
JP2007508298A5 true JP2007508298A5 (enExample) 2007-05-31

Family

ID=34422197

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006533831A Ceased JP2007508298A (ja) 2003-10-08 2004-07-23 2−メチレン−19−ノル−ビタミンd化合物を用いた炎症性腸疾患の治療

Country Status (10)

Country Link
US (2) US7704980B2 (enExample)
EP (1) EP1673095B1 (enExample)
JP (1) JP2007508298A (enExample)
AT (1) ATE448788T1 (enExample)
AU (1) AU2004283073B2 (enExample)
CA (1) CA2541991A1 (enExample)
DE (1) DE602004024221D1 (enExample)
ES (1) ES2338428T3 (enExample)
NZ (1) NZ546440A (enExample)
WO (1) WO2005039592A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2764577C (en) * 2009-08-03 2017-12-19 Wisconsin Alumni Research Foundation Method of preventing renal disease and treating symptoms thereof
US20110237557A1 (en) * 2010-03-23 2011-09-29 Deluca Hector F Diastereomers of 2-methylene-19-nor-22-methyl-1alpha,25-dihydroxyvitamin d3
US8604009B2 (en) * 2010-03-23 2013-12-10 Wisconsin Alumni Research Foundation (20S)-2-methylene-19-nor-22-dimethyl-1α,25-dihydroxyvitamin D3 and (20R)-2-methylene-19-nor-22-dimethyl-1α,25-hydroxyvitamin D3
US8664206B2 (en) 2010-03-23 2014-03-04 Wisconsin Alumni Research Foundation Diastereomers of 2-methylene-19-nor-22-methyl-1α,25-dihydroxyvitamin D3
FR2961401B1 (fr) * 2010-06-17 2013-04-05 Laetitia Mathez Composition anti-inflammatoire
CN102631354B (zh) * 2011-02-11 2015-01-21 广东泰禾医药科技有限公司 含维生素d3和二甲双胍的药物组合物
WO2012166938A2 (en) 2011-06-03 2012-12-06 Wisconsin Alumni Research Foundation (22e)-2-methylene-26,27-cyclo-22-dehydro-1alpha-hydroxy-19-norvitamin d3 derivatives
US20130295083A1 (en) * 2012-05-02 2013-11-07 Wisconsin Alumni Research Foundation 2a-Methyl-19-nor-(20S)-1a,25-dihydroxyvitamin D3 (2AMD) or 2 methylene-19-nor-(20S)-1a,25-dihydroxyvitamin D3 (2MD) Support Survival and Function of Transplanted Islet Cells In Type 1 Diabetes
HK1206600A1 (en) 2012-06-29 2016-01-15 Wisconsin Alumni Research Foundation USE OF 2-METHYLENE-19-NOR-(20S)-1α,25-DIHYDROXYVITAMIN D3 TO TREAT SECONDARY HYPERPARATHYROIDISM
US9370527B2 (en) 2012-12-28 2016-06-21 The Regents Of The University Of Michigan Amelioration of intestinal fibrosis and treatment of Crohn's disease
US9539264B2 (en) 2014-12-30 2017-01-10 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics
US10369161B2 (en) 2014-12-30 2019-08-06 Wisconsin Alumni Research Foundation Use of 2-methylene-19-NOR-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat primary hyperparathyroidism
WO2017184262A1 (en) * 2016-04-18 2017-10-26 Wisconsin Alumni Research Foundation Use of 2amd and 2md to treat fibrosis

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4221961A1 (de) 1992-06-30 1994-01-05 Schering Ag 22-En-25-oxa-Derivate in der Vitamin D-Reihe, Verfahren zu ihrer Herstellung, diese Derivate enthaltenen pharmazeutische Präparate sowie deren Verwendung als Arzneimittel
IL107185A (en) 1992-10-06 1998-02-22 Schering Ag Vitamin d, 25-carboxylic acid derivatives and pharmaceutical compositions containing the same
US5981597A (en) * 1995-02-13 1999-11-09 Trustees Of The University Of Pennsylvania Differentiating agents for the treatment of inflammatory intestinal diseases
US5843928A (en) * 1997-03-17 1998-12-01 Wisconsin Alumni Research Foundation 2-alkylidene-19-nor-vitamin D compounds
US6392071B1 (en) * 1997-03-17 2002-05-21 Wisconsin Alumni: Research Foundation 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds
US6358939B1 (en) * 1999-12-21 2002-03-19 Northern Lights Pharmaceuticals, Llc Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease
US6989377B2 (en) * 1999-12-21 2006-01-24 Wisconsin Alumni Research Foundation Treating vitamin D responsive diseases
US6806262B2 (en) * 2000-05-31 2004-10-19 Wisconsin Alumni Research Foundation 2-ethyl and 2-ethylidene-19-nor-vitamin D compounds
AU7544501A (en) * 2000-09-08 2002-03-22 Wisconsin Alumni Res Found 1alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol and its therapeutic applications
WO2003051828A2 (en) * 2001-12-13 2003-06-26 Wisconsin Alumni Research Foundation (20s)-1alpha-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
US6566352B1 (en) * 2002-02-18 2003-05-20 Wisconsin Alumni Research Foudation 1 α-hydroxy-2-methylene-19-nor-pregnacalciferol and its uses
US7259143B2 (en) * 2002-09-05 2007-08-21 Wisconsin Alumni Research Foundation Method of extending the dose range of vitamin D compounds

Similar Documents

Publication Publication Date Title
JP2007508298A5 (enExample)
KR101178318B1 (ko) 효과적인 의약의 사용법 및 부작용 발현의 방어에 관한방법
RU2490272C2 (ru) Макроциклические ингибиторы серинпротеазы
JP2007530577A5 (enExample)
JP2008526999A5 (enExample)
CA2549801A1 (en) Use of treprostinil to improve kidney functions
JP2009507838A5 (enExample)
JP2004502638A5 (enExample)
JP2015512860A5 (enExample)
JP2011516511A5 (enExample)
AU2018260616B2 (en) Treating and preventing kidney damage
JP2007502832A5 (enExample)
JP2008520690A5 (enExample)
JP2006523239A5 (enExample)
KR970707089A (ko) 18, 19-디노르-비타민 D 화합물(18,19-Dinor-Vitamin D Compounds)
RU2012150501A (ru) Противораковые стероидные лактоны, ненасыщенные в положении 7(8)
JP2007504168A5 (enExample)
CA2516233A1 (en) 2-propylidene-19-nor-vitamin d compounds
JP2006514681A5 (enExample)
JP2005527558A5 (enExample)
JP2007532540A5 (enExample)
WO2008068429A3 (fr) Composition pour la prevention et/ou le traitement des maladies associees a la surexpression du tnf et/ou de l'il-12
CA2597624A1 (en) 2-methylene-19-nor-(20s-24s)-1.alpha.,25-dihydroxyvitamin-d2
WO2012121957A1 (en) Combination
CA2562535A1 (en) 2-alkylidene-18,19-dinor-vitamin d compounds